Current-label answer
Both branded tirzepatide labels carry an acute-pancreatitis warning
The current Eli Lilly Mounjaro and Zepbound prescribing information was updated April 22, 2026. Each label says acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or the branded tirzepatide product. Each directs clinicians to watch for persistent or severe abdominal pain, sometimes radiating to the back and sometimes occurring with nausea or vomiting, and to discontinue the product and initiate appropriate management if pancreatitis is suspected.
- Mounjaro is labeled for adults and pediatric patients age 10 and older with type 2 diabetes; Peptide12 provides adult care and should not misstate the broader manufacturer label.
- Zepbound is labeled for chronic weight management in specified patients and for moderate to severe obstructive sleep apnea in adults with obesity; product indications and study populations are not interchangeable.
- A warning means the symptom pattern deserves attention. It does not prove that every episode of nausea or abdominal discomfort is pancreatitis, and a web page cannot diagnose it.
Product-specific evidence
The label numbers should not be pooled into one personal risk estimate
The Mounjaro label reports 14 adjudication-confirmed acute-pancreatitis events in 13 treated adults, or 0.23 patients per 100 years of exposure, versus 3 events in 3 comparator-treated patients, or 0.11 per 100 years of exposure. In pooled Zepbound weight-reduction Studies 1 and 2, 0.2% of treated patients and 0.2% of placebo patients had adjudication-confirmed acute pancreatitis. The Zepbound label separately reports an exposure-adjusted rate of 0.84 patients per 100 years in pooled obstructive-sleep-apnea studies and 0 in placebo. These are different programs, populations, comparators, and measures—not a head-to-head comparison or a forecast for an individual patient.
- Do not combine counts, percentages, and exposure-adjusted rates into one universal “tirzepatide pancreatitis rate.”
- A similar percentage in one pooled comparison does not erase the label warning, and a reported event does not by itself prove how tirzepatide contributed in a particular patient.
- Branded clinical-trial figures do not establish the safety, incidence, potency, or quality of a compounded preparation or research-use product.
Symptoms and urgent assessment
Persistent or severe abdominal pain should not be managed as routine nausea
NIDDK describes upper-abdominal pain that may spread to the back as the main symptom of pancreatitis and notes that acute pancreatitis can also involve nausea, vomiting, fever, a fast heartbeat, and a swollen or tender abdomen. Tirzepatide can also overlap with more common digestive symptoms, gallbladder problems, dehydration, and other causes of abdominal pain. Location and timing alone cannot safely distinguish them at home, especially when pain is severe, persistent, worsening, or paired with systemic symptoms.
- Use prompt in-person care for severe or persistent abdominal pain, pain spreading to the back, repeated vomiting, inability to keep fluids down, fainting, confusion, fever, jaundice, a tender or swollen abdomen, or rapidly worsening symptoms.
- Record pain location, severity and duration; nausea or vomiting; fever; bowel changes; food and fluid tolerance; urine output; glucose readings when relevant; and any recent illness, alcohol exposure, or clinician-directed treatment change.
- Do not wait for a routine refill visit, take an extra or partial injection, copy a dose hold or restart schedule, or use supplements, enzymes, fasting, detoxes, or alcohol to test whether symptoms improve.
Prior pancreatitis and other risks
A prior episode is a clinician-review question, not an automatic online answer
Prior pancreatitis is not listed among the contraindications in the current Mounjaro or Zepbound labels, but that does not establish automatic eligibility, safety, or a universal waiting period. A clinician should review what caused the prior episode, how it was confirmed, whether it recurred, current symptoms, gallstones or gallbladder disease, triglycerides, alcohol use, diabetes control, kidney and liver history, other medicines, and access to urgent follow-up before making a prescribing or refill decision.
- Bring emergency, hospital, imaging, procedure, and laboratory records when available, including lipase or amylase results and any gallbladder or triglyceride findings.
- Share insulin, sulfonylureas, other diabetes medicines, diuretics, medicines associated with pancreatitis, supplements, and changes in alcohol use or hydration.
- Do not hide prior pancreatitis to obtain treatment, assume a normal past scan guarantees future safety, or switch from a branded product to a compounded vial to bypass the review.
Compounded product and telehealth boundary
A compounded prescription is not FDA-approved Mounjaro or Zepbound
Mounjaro and Zepbound are FDA-approved finished tirzepatide products with manufacturer labels, specific indications, presentations, and clinical programs. A patient-specific compounded tirzepatide preparation is not FDA-approved Mounjaro, Zepbound, or an FDA-approved generic finished product. Its concentration, inactive ingredients, container, storage, beyond-use date, and pharmacy instructions may differ. A responsible telehealth review should confirm the actual package or pharmacy label and provide a practical urgent-care pathway before prescribing or refilling.
- Preserve the product name, manufacturer or dispensing pharmacy, indication, strength or concentration, container, refill or lot details, storage history, and a photo of the current label.
- Avoid research-use vials, counterfeit pens, unlabeled syringes, copied unit charts, no-prescription sellers, or claims that an additive prevents pancreatitis or makes tirzepatide safer.
- Contact the responsible clinician for product-specific next steps, but use local urgent or emergency care when the symptom pattern cannot safely wait for a portal response.